Arcutis appoints Rob Scott, MD to board of directors

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026.¹ The appointment was disclosed in an 8-K filing and accompanying press release dated October 28, 2026.

According to the filing, on October 23, 2026, the Board increased the authorized number of directors from ten to eleven and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee.¹ Dr. Scott was appointed as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders.¹ The Board determined that Dr. Scott qualifies as an independent director under applicable SEC and Nasdaq listing standards.¹

Dr. Scott's background includes serving as Chief Medical Officer and Head of Development of AbbVie Inc. from April 2016 until his retirement in April 2020.¹ He previously held roles at Amgen Inc. as Vice President, Global Development and Therapeutic Area Head from November 2010 to March 2016,¹ as well as positions at Cerenis Therapeutics, AtheroGenics, and Pfizer Inc.

On compensation, the filing states Dr. Scott received an initial stock option award exercisable for 20,507 shares of the Company's common stock, and is eligible for a prorated annual equity award fair valued at approximately $350,000, allocated 65% to stock options and 35% to restricted stock units, along with a prorated annual cash retainer of $50,000 for Board service and $5,000 for committee service.¹

The company also noted there is no arrangement or understanding between Dr. Scott and any other person pursuant to which he was selected as a director, no family relationships between Dr. Scott and the Company's other directors or executive officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.¹